Raludotatug deruxtecan
Phase 2Recruiting 0 views this week 0 watching⚡ Active
Interest: 42/100
42
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Solid Tumor
Conditions
Advanced Solid Tumor, Metastatic Solid Tumors
Trial Timeline
Jan 6, 2025 → Sep 30, 2027
NCT ID
NCT06660654About Raludotatug deruxtecan
Raludotatug deruxtecan is a phase 2 stage product being developed by Daiichi Sankyo for Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06660654. Target conditions include Advanced Solid Tumor, Metastatic Solid Tumors.
What happened to similar drugs?
16 of 20 similar drugs in Advanced Solid Tumor were approved
Approved (16) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
15
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06660654 | Phase 2 | Recruiting |
Competing Products
20 competing products in Advanced Solid Tumor